Otsuka Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo. It develops, manufactures, and markets prescription drugs, consumer healthcare products, and related therapies, with a focus on areas such as oncology, central nervous system disorders, and infectious diseases.
The company operates globally through subsidiaries and partnerships. It is involved in research and development of novel treatments, including investigational oncology assets developed in collaboration with partners such as Taiho Pharmaceutical and Astex Pharmaceuticals.
Also known as Otsuka Pharmaceutical, OPC, and 大塚製薬.
Supports calderasib plus pembrolizumab in PD‑L1 ≥1% newly diagnosed metastatic KRAS G12C NSCLC; positive Phase 1 KANDLELIT‑001 data; multiple Phase 3 trials planned; developed with Taiho/Astex
